Next report date
Report period
Q1 2024
EPS estimate
−0.21USD
Revenue estimate
6.36 MUSD
−1.4588USD
−257.83 MUSD
176.23 MUSD
183.15 M
About Sangamo Therapeutics, Inc.
Sector
Industry
CEO
Alexander D. Macrae
Website
Headquarters
Richmond
Employees (FY)
405
Founded
1995
FIGI
BBG00JRY9H89
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0R1D is 0.5189 USD — it has increased by 5.92% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange SANGAMO THERAPEUTICS INC COM USD0.01 stocks are traded under the ticker 0R1D.
SANGAMO THERAPEUTICS INC COM USD0.01 is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
0R1D stock is 5.82% volatile and has beta coefficient of 1.51. Check out the list of the most volatile stocks — is SANGAMO THERAPEUTICS INC COM USD0.01 there?
0R1D earnings for the last quarter are −0.59 USD per share, whereas the estimation was −0.32 USD resulting in a −85.03% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about SANGAMO THERAPEUTICS INC COM USD0.01 earnings.
SANGAMO THERAPEUTICS INC COM USD0.01 revenue for the last quarter amounts to 9.40 M USD despite the estimated figure of 9.36 M USD. In the next quarter revenue is expected to reach 8.11 M USD.
Yes, you can track SANGAMO THERAPEUTICS INC COM USD0.01 financials in yearly and quarterly reports right on TradingView.
0R1D stock has risen by 8.10% compared to the previous week, the month change is a 14.33% fall, over the last year SANGAMO THERAPEUTICS INC COM USD0.01 has showed a 66.52% decrease.
0R1D net income for the last quarter is −60.30 M USD, while the quarter before that showed −104.16 M USD of net income which accounts for 42.11% change. Track more SANGAMO THERAPEUTICS INC COM USD0.01 financial stats to get the full picture.
Today SANGAMO THERAPEUTICS INC COM USD0.01 has the market capitalization of 105.46 M, it has decreased by 5.89% over the last week.
No, 0R1D doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0R1D shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANGAMO THERAPEUTICS INC COM USD0.01 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 405.00 employees. See our rating of the largest employees — is SANGAMO THERAPEUTICS INC COM USD0.01 on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SANGAMO THERAPEUTICS INC COM USD0.01 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SANGAMO THERAPEUTICS INC COM USD0.01 stock shows the sell signal. See more of SANGAMO THERAPEUTICS INC COM USD0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SANGAMO THERAPEUTICS INC COM USD0.01 future price: according to them, 0R1D price has a max estimate of 8.00 USD and a min estimate of 1.00 USD. Read a more detailed SANGAMO THERAPEUTICS INC COM USD0.01 forecast: see what analysts think of SANGAMO THERAPEUTICS INC COM USD0.01 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANGAMO THERAPEUTICS INC COM USD0.01 EBITDA is −94.05 M USD, and current EBITDA margin is −52.26%. See more stats in SANGAMO THERAPEUTICS INC COM USD0.01 financial statements.